tiprankstipranks
Trending News
More News >
Retractable Technologies (RVP)
:RVP
US Market

Retractable Technologies (RVP) AI Stock Analysis

Compare
434 Followers

Top Page

RVP

Retractable Technologies

(RVP)

Select Model
Select Model
Select Model
Neutral 46 (OpenAI - 4o)
Rating:46Neutral
Price Target:
$0.80
▼(-1.95% Downside)
The overall stock score is primarily influenced by the company's moderate financial performance and weak technical indicators. The negative P/E ratio further impacts the valuation negatively. Despite a strong balance sheet, the lack of profitability and cash flow challenges pose significant risks.
Positive Factors
Strong Balance Sheet
A strong balance sheet with minimal leverage risk provides financial stability and flexibility, supporting long-term operational resilience.
Innovative Technology Designation
Recognition for innovation can enhance market reputation and competitive positioning, potentially driving future sales and partnerships.
Improved Gross Margin
Improved gross margins indicate better cost management and pricing strategy, which can enhance profitability over time.
Negative Factors
Profitability Challenges
Ongoing profitability challenges suggest operational inefficiencies, which could hinder long-term financial performance and growth.
Revenue Volatility
Revenue volatility can disrupt financial planning and stability, affecting the company's ability to sustain growth and market position.
Cash Flow Constraints
Cash flow constraints can limit the company's ability to invest in growth opportunities and meet financial obligations, impacting long-term viability.

Retractable Technologies (RVP) vs. SPDR S&P 500 ETF (SPY)

Retractable Technologies Business Overview & Revenue Model

Company DescriptionRetractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally. It offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes. The company distributes its products through general line and specialty distributors, as well as through international distributors; and a direct marketing network. Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas.
How the Company Makes MoneyRetractable Technologies generates revenue primarily through the sale of its retractable syringes and safety needle products. The company sells these products directly to healthcare providers and distributors, establishing long-term contracts and partnerships that ensure a steady stream of orders. Additionally, RVP benefits from government contracts and participation in group purchasing organizations, which enable it to reach a broader customer base. The company may also explore partnerships with other healthcare firms to expand its product offerings or enter new markets, contributing to its overall earnings.

Retractable Technologies Financial Statement Overview

Summary
Retractable Technologies faces challenges with profitability and cash flow generation, despite maintaining a strong balance sheet with low leverage. Revenue growth has been inconsistent, and the company needs to address operational inefficiencies to improve margins and cash flow stability. The financial health is moderate, with potential risks from ongoing losses and cash flow constraints.
Income Statement
45
Neutral
Retractable Technologies has experienced significant revenue volatility, with a recent TTM revenue growth of 13.09% following a previous decline. However, profitability metrics are concerning, with negative gross and net profit margins in the TTM period, indicating operational challenges. The EBIT and EBITDA margins have also deteriorated, reflecting ongoing cost pressures.
Balance Sheet
60
Neutral
The company maintains a strong balance sheet with a low debt-to-equity ratio of 0.015, indicating minimal leverage risk. However, the negative return on equity in the TTM period suggests inefficiencies in generating returns from shareholders' equity. The equity ratio remains stable, highlighting a solid capital structure.
Cash Flow
50
Neutral
Cash flow performance is mixed, with a positive free cash flow growth rate of 10.09% in the TTM period. However, negative operating cash flow and a high free cash flow to net income ratio indicate potential liquidity issues. The company needs to improve its cash generation capabilities to support operations.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue38.16M33.05M43.60M94.82M188.38M81.86M
Gross Profit-2.62M-1.03M9.11M28.25M95.35M37.01M
EBITDA-829.42K4.17M-1.24M9.94M76.44M27.17M
Net Income-8.74M-11.89M-7.01M5.08M56.06M24.22M
Balance Sheet
Total Assets147.09M160.72M179.67M210.74M213.15M104.97M
Cash, Cash Equivalents and Short-Term Investments33.05M44.56M47.29M49.38M42.43M25.65M
Total Debt1.07M1.23M1.54M2.92M4.24M3.74M
Total Liabilities70.62M73.55M80.38M104.21M113.98M55.09M
Stockholders Equity76.47M87.17M99.29M106.54M99.17M49.88M
Cash Flow
Free Cash Flow-13.55M-13.00M1.91M-61.95K-25.57M-2.05M
Operating Cash Flow-12.04M-11.56M2.77M16.77M32.79M19.00M
Investing Cash Flow8.78M3.66M-10.76M-31.20M-63.04M-19.33M
Financing Cash Flow-551.50K-535.43K941.64K4.99M41.84M11.96M

Retractable Technologies Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.82
Price Trends
50DMA
0.86
Negative
100DMA
0.84
Negative
200DMA
0.77
Positive
Market Momentum
MACD
>-0.01
Negative
RSI
45.64
Neutral
STOCH
63.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RVP, the sentiment is Negative. The current price of 0.82 is below the 20-day moving average (MA) of 0.82, below the 50-day MA of 0.86, and above the 200-day MA of 0.77, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 45.64 is Neutral, neither overbought nor oversold. The STOCH value of 63.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RVP.

Retractable Technologies Risk Analysis

Retractable Technologies disclosed 17 risk factors in its most recent earnings report. Retractable Technologies reported the most risks in the "Macro & Political" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Retractable Technologies Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
$218.38M-8.32-170.24%19.61%-3.42%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
48
Neutral
$171.44M-2.95-15.30%-43.95%-620.21%
46
Neutral
$24.61M-3.69-8.05%-0.95%58.17%
42
Neutral
$216.33M-5.57-27.19%30.55%-340.19%
41
Neutral
$25.18M-3.87-136.47%0.59%-39.76%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
RVP
Retractable Technologies
0.82
0.20
32.26%
OSUR
Orasure Technologies
2.39
-1.23
-33.98%
STXS
Stereotaxis
2.34
-0.01
-0.43%
MLSS
Milestone Scientific
0.32
-0.55
-63.22%
SMTI
Sanara MedTech
24.21
-9.90
-29.02%
STSS
Sharps Technology, Inc.
2.22
-552.78
-99.60%

Retractable Technologies Corporate Events

Business Operations and StrategyFinancial Disclosures
Retractable Technologies Reports Q3 2025 Financial Results
Neutral
Nov 14, 2025

On November 14, 2025, Retractable Technologies reported its financial results for the third quarter of 2025, showing net sales of $10.1 million and an operating loss of $3.7 million, compared to $10.3 million in sales and a $5.1 million loss in the same period last year. The company has been impacted by tariffs on imported products, leading to increased domestic production, which now accounts for 38.3% of its manufacturing. Despite a decrease in overall unit sales, the company improved its gross margin due to a favorable product mix and reduced tariff costs. International revenues increased by 25% for the quarter, although the average selling price declined. Retractable also received an Innovative Technology designation from Vizient®.

Dividends
Retractable Technologies Declares Dividend for Preferred Stock
Positive
Sep 30, 2025

On September 30, 2025, Retractable Technologies announced a dividend declaration for its Series II and Series III Class B Convertible Preferred Stock shareholders. This announcement reflects the company’s commitment to providing returns to its investors, potentially enhancing shareholder value and market confidence.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 09, 2025